Insider

GE HealthCare Technologies Inc.

GEHC Health Care · 3 analyses · 6 expectations tracked

GE HealthCare Technologies reported $5.5B in revenue (+7.2% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 6 open management expectations for this company.

Mentioned in recent filings: Ukraine Russia Tariffs

What changed

Company history

October 2026

GE HealthCare Technologies Inc.: 12 recorded developments from 1 official source in 2026-10.

  • 2026-10-28: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), quarter 2026-07-01 to 2026-09-30: 5,513,000,000 USD (5.5 billion; 5,513 million); same period a year earlier (2025-07-01 to 2025-09-30): 5,143,000,000 USD (5.1 billion; 5,143 million); change +7.2% Source
  • 2026-10-28: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), year to date 2026-01-01 to 2026-09-30: 15,939,000,000 USD (15.9 billion; 15,939 million); same period a year earlier (2025-01-01 to 2025-09-30): 14,927,000,000 USD (14.9 billion; 14,927 million); change +6.8% Source
  • 2026-10-28: Gross profit (us-gaap:GrossProfit), quarter 2026-07-01 to 2026-09-30: 2,224,000,000 USD (2.2 billion; 2,224 million); same period a year earlier (2025-07-01 to 2025-09-30): 1,990,000,000 USD (2 billion; 1,990 million); change +11.8% Source
  • 2026-10-28: Gross profit (us-gaap:GrossProfit), year to date 2026-01-01 to 2026-09-30: 6,381,000,000 USD (6.4 billion; 6,381 million); same period a year earlier (2025-01-01 to 2025-09-30): 5,987,000,000 USD (6 billion; 5,987 million); change +6.6% Source
  • 2026-10-28: Operating income (us-gaap:OperatingIncomeLoss), quarter 2026-07-01 to 2026-09-30: 805,000,000 USD (805 million); same period a year earlier (2025-07-01 to 2025-09-30): 653,000,000 USD (653 million); change +23.3% Source
  • 2026-10-28: Operating income (us-gaap:OperatingIncomeLoss), year to date 2026-01-01 to 2026-09-30: 2,058,000,000 USD (2.1 billion; 2,058 million); same period a year earlier (2025-01-01 to 2025-09-30): 1,936,000,000 USD (1.9 billion; 1,936 million); change +6.3% Source
  • 2026-10-28: Net income (us-gaap:NetIncomeLoss), year to date 2026-01-01 to 2026-09-30: 1,564,000,000 USD (1.6 billion; 1,564 million); same period a year earlier (2025-01-01 to 2025-09-30): 1,495,000,000 USD (1.5 billion; 1,495 million); change +4.6% Source
  • 2026-10-28: Research and development expense (us-gaap:ResearchAndDevelopmentExpense), quarter 2026-07-01 to 2026-09-30: 320,000,000 USD (320 million); same period a year earlier (2025-07-01 to 2025-09-30): 292,000,000 USD (292 million); change +9.6% Source
  • 2026-10-28: Research and development expense (us-gaap:ResearchAndDevelopmentExpense), year to date 2026-01-01 to 2026-09-30: 988,000,000 USD (988 million); same period a year earlier (2025-01-01 to 2025-09-30): 937,000,000 USD (937 million); change +5.4% Source
  • 2026-10-28: Operating cash flow (us-gaap:NetCashProvidedByUsedInOperatingActivities), year to date 2026-01-01 to 2026-09-30: 1,365,000,000 USD (1.4 billion; 1,365 million); same period a year earlier (2025-01-01 to 2025-09-30): 937,000,000 USD (937 million); change +45.7% Source
  • 2026-10-28: Cash and cash equivalents (us-gaap:CashAndCashEquivalentsAtCarryingValue), as of 2026-09-30: 2,826,000,000 USD (2.8 billion; 2,826 million); previous balance (2025-12-31): 4,492,000,000 USD (4.5 billion; 4,492 million); change -37.1% Source
  • 2026-10-28: Shareholders' equity (us-gaap:StockholdersEquity), as of 2026-09-30: 11,614,000,000 USD (11.6 billion; 11,614 million); previous balance (2025-12-31): 10,379,000,000 USD (10.4 billion; 10,379 million); change +11.9% Source

September 2026

GE HealthCare Technologies Inc.: 7 recorded developments from 2 official sources in 2026-09.

  • 2026-09-22: GE HealthCare announced the appointment of Pascal Desroches to its Board of Directors, effective January 4, 2027. Source
  • 2026-09-22: Upon joining the Board, Mr. Desroches will receive compensation in accordance with the Company’s compensation program for non-employee directors. Source
  • 2026-09-22: The Company will also enter into an indemnification agreement with Mr. Desroches. Source
  • 2026-09-22: There is no arrangement or understanding between Mr. Desroches and any other person pursuant to which he was selected as a director. Source
  • 2026-09-22: On September 22, 2026, the Company issued a press release announcing the appointment of Pascal Desroches to its Board. Source
  • 2026-09-22: A copy of the press release is furnished as Exhibit 99. Source
  • 2026-09-22: The information furnished pursuant to Item 7.01, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 30, 2026, filed October 28, 2026. SEC

LatestEarlierChange
Revenue quarter$5.5B$5.1B+7.2%
Operating income quarter$805M$653M+23.3%
Net income quarter$615M$446M+37.9%
Diluted EPS quarter$1.36$0.98+38.8%
Dividends per share quarter$0.04$0.07-42.9%
Operating cash flow year to date$1.4B$937M+45.7%
Cash and cash equivalents balance$2.8B$4.5B-37.1%
Long-term debt balance$10B$9.5B+5.0%

Next results expected around January 27, 2027 (estimate: the quarter ending about December 30, 2026 plus the 28 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Revenue by quarter, $B

5.3Q4 '24*15.1%4.8Q1 '2513.2%5Q2 '2513.1%5.1Q3 '2512.7%5.7Q4 '25*14.5%5.1Q1 '2610%5.3Q2 '2614%5.5Q3 '2614.6%
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
GE HealthCare Technologies Inc. GEHC$5.5B+7.2%14.6%
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Expectations and reality

Open

  • Taha Kass-Hout will resign as Chief Science and Technology Officer, with his last day at GE HealthCare being December 31, 2026.

    Said November 5, 2026 · Period named: December 31, 2026 · Source · Our article

    Not yet checked against later reports.

  • GE HealthCare raised its full-year 2026 guidance for Organic Revenue Growth to approximately 4.0%.

    Said October 28, 2026 · Period named: full-year 2026 · Source · Our article

    AI assessment, provisional no new evidence in later reports yet (as of November 5, 2026) · Later article

  • GE HealthCare raised its full-year 2026 guidance for Adjusted EPS to $4.95 - $5.05.

    Said October 28, 2026 · Period named: full-year 2026 · Source · Our article

    AI assessment, provisional no new evidence in later reports yet (as of November 5, 2026) · Later article

  • GE HealthCare raised its full-year 2026 guidance for Free Cash Flow to $1.6B+.

    Said October 28, 2026 · Period named: full-year 2026 · Source · Our article

    AI assessment, provisional no new evidence in later reports yet (as of November 5, 2026) · Later article

  • GE HealthCare raised its full-year 2026 guidance for Adjusted EBIT Margin to 15.5% - 15.7%.

    Said October 28, 2026 · Period named: full-year 2026 · Source · Our article

    AI assessment, provisional no new evidence in later reports yet (as of November 5, 2026) · Later article

  • GE HealthCare expects its acquisition of SOFIE Biosciences to close in the first half of 2027, subject to customary closing conditions and regulatory approvals.

    Said October 28, 2026 · Period named: first half of 2027 · Source · Our article

    AI assessment, provisional no new evidence in later reports yet (as of November 5, 2026) · Later article

What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.

Governance events

Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.

DateEventFiling
November 5, 2026Director or officer departure or appointment (8-K item 5.02)8-K
October 28, 2026Director or officer departure or appointment (8-K item 5.02)8-K
September 22, 2026Director or officer departure or appointment (8-K item 5.02)8-K
August 18, 2026Director or officer departure or appointment (8-K item 5.02)8-K

As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
November 4, 2026James SaccaroPlanned sale78,348—$6,731,613SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock37,336,302$2,440,674,082-0.4%Q3 2026
State Street20,997,119$1,372,581,669+0.6%Q3 2026
Geode Capital Management12,938,406$842,605,888+0.5%Q3 2026
Norges Bank (Norway's sovereign fund)5,823,524$372,763,771—Q2 2026
Fidelity (FMR)4,338,926$283,635,567+37.5%Q3 2026
Citadel Advisors1,744,748$114,054,177-26.3%Q3 2026
Millennium Management796,855$52,090,411+175.1%Q3 2026
D. E. Shaw & Co.418,089$26,761,877-11.1%Q2 2026
Capital Research Global Investors380,821$24,894,273-3.4%Q3 2026
Renaissance Technologies254,100$18,086,838—Q1 2026
Wellington Management109,311$7,145,660+1.8%Q3 2026
Bridgewater Associates14,808$967,999-5.0%Q3 2026
Two Sigma Investments12,127$792,742-6.6%Q3 2026
T. Rowe Price1,063,692$69,534-4.5%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.